However, in the subset of patients with stage IV lung adenocarcinoma—a population characterized by a high burden of osseous metastasis and distinct molecular features (e.g., > 50% EGFR mutation rate)—clinical response to denosumab is notably heterogeneous. Here, EGFR is linked to lung adenocarcinoma.